Vaccine Joint Development with BioComo and Mie University Japan
MediciNova Announces SARS-CoV-2 Vaccine Joint Development with BioComo and Mie University Japan
through our joint development with MediciNova, we will proceed with further non-clinical and clinical trial development as quickly as possible globally and not only in Japan.
We are confident that the BC-PIV SARS-CoV-2 vaccine will be successful and hope that this vaccine will be available in a clinical setting as soon as possible and will be the “gospel” for the people in the world.”
www.globenewswire.co...niversity-Japan.html
www.fool.com/investi...s-soaring-today.aspx
through our joint development with MediciNova, we will proceed with further non-clinical and clinical trial development as quickly as possible globally and not only in Japan.
We are confident that the BC-PIV SARS-CoV-2 vaccine will be successful and hope that this vaccine will be available in a clinical setting as soon as possible and will be the “gospel” for the people in the world.”
www.globenewswire.co...niversity-Japan.html
www.fool.com/investi...s-soaring-today.aspx